Clinical Trial Detail

NCT ID NCT01623349
Title Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

ovarian cancer

triple-receptor negative breast cancer

Therapies

Alpelisib + Olaparib

Buparlisib + Olaparib

Age Groups: adult senior

No variant requirements are available.